

**EPAD**

European Prevention of  
Alzheimer's Dementia Consortium



**efpia**



# EPAD

## European Prevention of Alzheimer Dementia

Serge Van der Geyten  
IMI EPAD Coordinator

IMI Roundtable

Alzheimer's Disease: Advancing Research Through Collaboration

8 November 2016 - European Parliament, Brussels, Belgium

[www.ep-ad.org](http://www.ep-ad.org)

@IMI\_EPAD



# Acknowledgments

---

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.



innovative  
medicines  
initiative



INFOGRAPHIC


# The global impact of dementia



Around the world, there will be 9.9 million new cases of dementia in 2015,

**one every 3 seconds**

46.8 million people worldwide are living with dementia in 2015. This number will almost double every 20 years.



Much of the increase will take place in low and middle income countries (LMICs): in 2015, 58% of all people with dementia live in LMICs, rising to 63% in 2030 and 68% in 2050.



The total estimated worldwide cost of dementia in 2015 is US\$ 818 billion. By 2018, dementia will become a trillion dollar disease, rising to **US\$ 2 trillion by 2030**

If global dementia care were a country, it would be the **18th largest economy** in the world exceeding the market values of companies such as Apple and Google



(source: Forbes 2015 ranking).




This map shows the estimated number of people living with dementia in each world region in 2015.

We must now involve more countries and regions in the global action on dementia.





# The Sad Truth



**123** Total Unsuccessful Drugs | **4** Total Approved Medicines

Source: PhRMA analysis of Adis R&D Insight Database, 17 June 2015.





# Why EPAD?

**Limited Translatability  
of existing Disease  
Models**

**Lack of validated, non-  
invasive biomarkers**

**Scientific Knowledge  
Gap**

- AD mechanism
- Slow data sharing

**Inefficient Trial System**

- long duration
- slow recruitment & high screen failure rates
- lack of suitable outcome measures & regulatory acceptance


**EPAD**

European Prevention of  
Alzheimer's Dementia Consortium

**EPAD aims to Develop a Platform to test treatments for the  
Secondary Prevention of Alzheimer's Dementia**




# EPAD Stepped Approach







# EPAD Project Overview





## Academia



## EFPIA



## SMEs



## Other industry



## Patient Organisation







# EPAD Collaborating to prevent AD




ARUK Drug  
Discovery  
Institute



Target identification  
and development



Dementias  
Platform UK  
  
Deep and  
Frequent  
phenotyping




Trials ready cohorts and data



European  
Medical  
information  
Framework



Global Alzheimer's  
Prevention



Proof of concept  
trials





## Acknowledgments

### EPAD National Leads &TDCs

- Philip Scheltens
- Niels Prins
- Bruno Velas
- Pierre-Jean Ousset
- Sandrine Andrieu
- Giovanni Frisoni
- Ana Campillo
- Maura Parapini
- Craig Ritchie
- Natalie Jenkins
- José Luis Molinuevo
- Karine Fauria
- Miia Kivipelto
- Alina Solomon
- Stefan Borg
- and many more

### WP4 LCS protocol team

- Miia Kivipelto
- Alina Solomon
- Stefan Borg
- Craig Ritchie
- Judi Syson
- Catherine Debove
- Mila Etroploski
- Brian Tom

### EPAD ExCom

- José Luis Molinuevo
- Simon Lovestone
- Craig Ritchie
- Andy satlin
- Luc Truyen
- Serge Van der Geyten

### EPAD PMO

- Carlos Diaz
- Sandra Pla
- Lennert Steukers

### Scientific Advisory Groups

- Karen Ritchie
- Michael Ropacki
- Frederik Barkhof
- Julie Williams
- Bruno Dubois
- Carol Brayne

### Ethics

- Carol Brayne
- Shirlene Badger
- Richard Milne
- Edo Richard
- Krista Tromp
- Maartje Schermer

### Legal

- Wouter Deneyer
- Fiona Campbell
- Lindsay Hampton